ActivistsInvestorsTrumpPoliticiansSerenityCitriniBurrySemianalysisSwingTradeArbitrageSearch

$ALXO:NASDAQ · ALX ONCOLOGY HLDGS INC

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States.

More about this company

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer. It has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under phase 1b/2 trial for the treatment of breast cancer and other solid tumors; HER2 with an ADC, fam-trastuzumab deruxtecan-nxki, under phase 1 trial for the treatment of patients with breast cancer; ALX2004, under phase 1 clinical trial for treating solid tumors; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; and Sanofi with isatuximab and dexamethasone, under phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma. It has license agreements with Board of Trustees of Leland Stanford Junior University. The company was incorporated in 2015 and is headquartered in South San Francisco, California.

Sector: health

Conviction from: NASDAQ

52-week range: 0.86002.66

2 tracked filer(s) hold this · 1 opened, 0 added, 0 trimmed in 30-SEP-2026

Aggregate 13FScore 70 — mean of 2 scored holder(s) · buyers (new/add) avg 75. Higher = the smart money in this name has the better track record.

Filer13FScoreThis quarterSharesValue% of their book
Steve Cohen / Point7275New buy36,134$50,2260.0%
Andrew Law / Caxton64Holds (flat)20,946$29,1151.0%

Beyond 13F — activists, insiders, politicians & research

Activist 13D filings daily digest →

FiledFormActivist% of classConviction
2026-02-04SCHEDULE 13D/AvenBio Global Strategic Fund, L.P.10.0%Medfiling

Insider open-market buys daily digest →

FiledInsiderRoleSharesValue
2026-02-04GOODMAN COREY Sdirector+10%-owner3,184,713$4,999,999Form 4

Every tracked holder of this name, sorted new → added → flat → trimmed. Shares = reported 13F share count; Value as reported (a few managers file values in $thousands). Generated 2026-11-17.